Financing channel feed – Endpoints News

Financing channel feed

A one-time pop singer with mega-money star connections hatches a $100M plan to invest in ‘contrarian’ biotech ideas

3 years ago

Vaxcyte's data lead to $600M haul, while Taysha looks to raise cash after Astellas deal

3 years ago

Recursion discreetly culls a rare disease program to focus on cancer, pulls in $150M private placement

3 years ago

In bid to keep itself afloat, tiny Diffusion Pharmaceuticals mulls out-licensing core tech or company sale

3 years ago

Gritstone bio secures PIPE financing as it unveils PhI data for vaccine candidate

3 years ago

Alto Neuroscience continues march toward the clinic with Series B, hoping to unveil data next year

3 years ago

In $23M deal, Syncona adds ex-Biogen partner and 20-year-old gene therapy outfit AGTC to portfolio

3 years ago

Tricida bet its future on one last readout for its CKD drug. Now that’s all but gone

3 years ago

A Texas-Illinois cancer biotech searches for more Series B capital two years after extension

3 years ago

The namesake behind Harvard’s Wyss Institute has made his fourth donation, this time to the tune of $350M

3 years ago

Playboy, digital health, electric vehicles and now cancer drugs: A mountainous SPAC journey

3 years ago

In a pandemic boom callback, David Liu's preclinical gene editing startup debuts on Nasdaq with $175M IPO

3 years ago

Scoop: Carisma stole CAR-M Thunder for a while, but a Utah biotech is quietly raising funds to enter the fray

3 years ago

A pair of storied neuroscience biotechs looks to raise nearly $450M combined (and maybe more) via public offerings

3 years ago

Backed by OrbiMed, Sanofi vet's startup tackles the many mutations of breast cancer at once

3 years ago

Can a little startup equipped with an Eli Lilly castoff make it big with an oncology IPO? In 2022?

3 years ago

Novartis-partnered Orionis secures $55M to push cytokine program into clinic

3 years ago

Drug discovery biotech looking into the ‘dark’ regions of the human genome picks up a $40M+ Series A

3 years ago

Scoop: After hep B setback, an OrbiMed-backed NASH biotech hunts for partners as it raises Series C

3 years ago

Backed by Bob Langer, former Harvard prof sets out to test a new way to deliver I/O drugs — during surgery

3 years ago

Tale of two SPACs: One strikes a deal as turbulent market forces another to dissolve

3 years ago

Scoop: With investor interest dried up in microbiome therapies, DermBiont pivots to other topicals and nears close of Series B

3 years ago

Josh Bilenker, Jeff Engelman quiet on everything behind their $735M 'outer edge' startup

3 years ago

Six biotechs merge to take on BridgeBio, Abeona in 'butterfly skin' disease, with eyes also set on Duchenne

3 years ago

First page Previous page 44 45 464748 49 50 Next page Last page